Live Medical Crossfire: How Do Recent Pathophysiological Findings in Pustular Psoriasis Have the Potential to Shape a New Treatment Paradigm?

Program overview: Pustular psoriasis outbreaks can be severe and life-threatening but early diagnosis is hindered by its rarity, heterogeneous presentation, and lack of consistent classification. At present there are no standard therapies and only limited evidence-based guidance with available agents. However, recent clinical, histological, and genetic evidence has provided new insights into the pathophysiology of pustular psoriasis, allowing for new therapeutic targets with novel treatments. During this live Medical Crossfire®, a multidisciplinary panel of experts will share their insights on diagnosis and disease severity assessment, possible pathophysiological pathways involved in the development of the disease, and the clinical profiles and mechanisms of action of available and emerging agents for the treatment of adults with pustular psoriasis. Throughout the program, there will be a focus on individualizing disease management to improve patient outcomes and quality of life. Participants will be encouraged to interact with the panel through audience response technology.

Host: Physicians’ Education Resource, LLC (PER) and supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals Inc.

Location: Sheraton Denver, Vail room

Date: Friday, March 20

Registration time: 6:30 p.m.

Program time: 7-8:30 p.m.

Register here.